phrykt

4D Molecular Therapeutics, Inc. (FDMT): who owns it and who trades it

As of Nov 16, 2026, FDMT insiders reported 25 open-market sales worth $5.4M and no purchases in the last 12 months, with 14% of the sale value made under pre-set 10b5-1 plans. The largest seller was David Kirn (Director), with $5M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling 4D Molecular Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns FDMT

157 funds and institutions reported FDMT shares worth $777M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jupiter Topco LLC with 11.5%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Jupiter Topco LLC11.5%
Ra Capital Management, L.P.10.1%
BlackRock, Inc.9.1%
Goldman Sachs Group Inc8.6%
Novo Holdings A/s6.5%
State Street Corp5.8%
Bvf Inc5.8%
T. Rowe Price Investment Management, Inc.5.0%
Adage Capital Partners Gp, L.l.c.4.5%
Trails Edge Capital Partners, LP4.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC5.75M11.54%$76.5M–
Ra Capital Management, L.P.5.05M10.14%$67.2MNo change
BlackRock, Inc.4.55M9.13%$60.5M+10%
Goldman Sachs Group Inc4.26M8.56%$56.6M+1%
Novo Holdings A/s3.25M6.53%$43.2M-11%
State Street Corp2.91M5.85%$38.7M+8%
Bvf Inc2.88M5.78%$38.3MNo change
T. Rowe Price Investment Management, Inc.2.51M5.05%$33.4M–
Adage Capital Partners Gp, L.l.c.2.25M4.52%$29.9M+40%
Trails Edge Capital Partners, LP2.23M4.48%$29.6M+71%
Vanguard Capital Management LLC2.10M4.22%$27.9M-4%
Armistice Capital, LLC2.00M4.02%$26.6MNo change
Geode Capital Management, LLC1.13M2.27%$15M+6%
Bank of America Corp1.12M2.25%$14.9M+15%
Evergreen Quality Fund GP, Ltd.951,4741.91%$12.7MNo change
Parkman Healthcare Partners LLC948,1841.90%$12.6M+81%
Dimensional Fund Advisors LP730,8571.47%$9.7M+40%
Deutsche Bank Ag\710,9421.43%$9.5M+0%
Citadel Advisors LLC687,5971.38%$9.1M+160%
Renaissance Technologies LLC614,5731.23%$8.2M+6%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, FDMT insiders reported $0 of open-market purchases and $5.4M of sales. 14% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$5.4M
25 trades, 3 people
Sales under a 10b5-1 plan
14%
Share of sale value
Latest trade
Oct 16, 2026
Filed Oct 20, 2026

Purchases and sales by month

$1.5M$1.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 16, 2026Scott BizilyChief Legal OfficerSale plan1,635$12.84$21KForm 4
Oct 5, 2026David KirnDirectorSale plan58,061$12.92$750KForm 4
Oct 5, 2026David KirnDirectorSale plan272$13.61$3.7KForm 4
Sep 16, 2026Scott BizilyChief Legal OfficerSale1,635$13.65$22.3KForm 4
Sep 14, 2026David KirnDirectorSale58,333$13.90$811KForm 4
Sep 1, 2026Scott BizilyChief Legal OfficerSale584$14.00$8.2KForm 4
Aug 19, 2026David KirnDirectorSale43,149$15.36$663KForm 4
Aug 19, 2026David KirnDirectorSale25,927$16.42$426KForm 4
Aug 17, 2026Scott BizilyChief Legal OfficerSale1,635$12.20$19.9KForm 4
Aug 13, 2026Scott BizilyChief Legal OfficerSale1,635$12.00$19.6KForm 4
Aug 4, 2026David KirnDirectorSale26,842$10.23$275KForm 4
Aug 3, 2026David KirnDirectorSale12,415$10.05$125KForm 4
Jul 10, 2026David KirnDirectorSale15,283$12.01$184KForm 4
Jul 10, 2026David KirnDirectorSale442$12.84$5.7KForm 4
Jul 9, 2026David KirnDirectorSale42,608$12.87$548KForm 4
Jun 30, 2026Scott BizilyChief Legal OfficerSale6,566$14.00$91.9KForm 4
Jun 23, 2026Scott BizilyChief Legal OfficerSale9,810$12.00$118KForm 4
Jun 22, 2026David KirnDirectorSale114,746$10.47$1.2MForm 4
Jun 1, 2026David KirnDirectorSale1,922$10.02$19.3KForm 4
Mar 20, 2026Ashoo GuptaVice presidentSale310$8.61$2.7KForm 4
Mar 20, 2026Ashoo GuptaVice presidentSale80$8.61$689Form 4
Dec 20, 2025Ashoo GuptaVice presidentSale310$8.68$2.7KForm 4
Dec 20, 2025Ashoo GuptaVice presidentSale79$8.68$686Form 4
Dec 16, 2025Scott BizilyChief Legal OfficerSale1,635$10.90$17.8KForm 4
Nov 17, 2025Scott BizilyChief Legal OfficerSale1,635$10.59$17.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David KirnSee Remarks, Director–$5MOct 5, 2026
Scott BizilyChief Legal Officer–$336KOct 16, 2026
Ashoo GuptaVP, Finance and Controller–$6.7KMar 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

FDMT short interest

10.90M FDMT shares are sold short. Over the last 12 reports the number of shares short went down 10%.

As of Oct 30, 2026, 10.90M FDMT shares were sold short, down 5.5% from the report before. At the average daily volume of 1.05M shares, buying them all back would take about 10.4 trading days (days to cover).

Shares short

10.90MMay 15Oct 3013.67M

Days to cover

10.4May 15Oct 3024.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.90M–-5%1.05M10.4
Oct 15, 202611.53M–+3%960,95512.0
Sep 30, 202611.24M–-6%1.20M9.3
Sep 15, 202612.01M–-1%647,40918.6
Aug 31, 202612.07M–-2%1.48M8.2
Aug 14, 202612.29M–+2%550,71422.3
Jul 31, 202612.04M–+6%680,47817.7
Jul 15, 202611.36M–-15%732,62315.5
Jun 30, 202613.31M–+3%1.46M9.1
Jun 15, 202612.93M–+6%782,37816.5
May 29, 202612.19M–+1%872,66314.0
May 15, 202612.08M–+1%633,23019.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

4D Molecular Therapeutics company events

4D Molecular Therapeutics filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Sep 28, 2026.

  1. Sep 28, 2026Announcement4D Molecular Therapeutics, Inc. reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. Jul 20, 2026Announcement4D Molecular Therapeutics, Inc. reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration population. 2-Year Data from PRISM Phase 2b Clinical Trial (Data Cutoff May 18, 2026): Trial and Patient Cohort Overview • The Phase… Filing
  4. Jun 29, 2026Agreement4D Molecular Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc., providing for term loans in an of up to $200.0 million, subject to the terms and conditions set forth therein. Filing
  5. Jun 22, 2026VoteReported shareholder vote results. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Mar 30, 2026LeadershipThe Board of Directors of 4D Molecular Therapeutics, Inc. appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately. Filing
  8. Mar 18, 2026ResultsReleased financial results. Filing
  9. Jan 26, 2026SharesSold new shares outside a public offering. Filing
  10. Jan 7, 2026LeadershipIn connection with his transition to a new part-time employment position, Fariborz Kamal, Ph.D., resigned as President and Chief Operating Officer of the Company effective immediately to pursue other opportunities. Filing
  11. Dec 10, 2025Announcement4D Molecular Therapeutics, Inc. announced its intention to implement protocol amendments to the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials of 4D-150 in wet AMD to increase target enrollment from 400 to 480 patients per trial. Filing
  12. Nov 17, 2025LeadershipKristian Humer joined 4D Molecular Therapeutics, Inc. as Chief Financial Officer and Principal Financial Officer. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

4D Molecular Therapeutics financials

Famous investors that hold FDMT

4 of the 50 well-known investors we track reported holding FDMT in their latest 13F filing. The largest position is Jim Simons's, worth $5.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026411,786$5.9M0.0%-33%
Ken Griffin · Citadel AdvisorsQ3 2026154,311$2.2M0.0%-78%
Israel Englander · Millennium ManagementQ3 2026136,373$2M0.0%New
Ken Fisher · Fisher Asset ManagementQ3 202658,546$838K0.0%-11%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named FDMT in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A7.3%
Nov 16, 2026Novo Holdings A/S13G/A5.4%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A7.3%
Nov 16, 2026Novo Holdings A/S13G/A5.4%
Nov 10, 2026STATE STREET CORPORATION13G4.5%
Nov 10, 2026STATE STREET CORPORATION13G4.5%

Questions about 4D Molecular Therapeutics, Inc. (FDMT) stock

Who owns the most FDMT stock?

The largest reported owner of 4D Molecular Therapeutics, Inc. (FDMT) is Jupiter Topco LLC, with 11.5% of the company. In total, 157 funds and institutions reported holding FDMT at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are FDMT insiders buying or selling?

In the last 12 months, FDMT insiders reported no open-market purchases and 25 sales worth $5.4M. The latest trade was on Oct 16, 2026. See every trade.

What is the short interest in FDMT?

As of Oct 30, 2026, 10.90M FDMT shares were sold short, down 5.5% from the report before. At the average daily volume of 1.05M shares, buying them all back would take about 10.4 trading days (days to cover). See the history.

Which famous investors hold FDMT?

4 of the 50 well-known investors we track reported FDMT in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $5.9M. See all holders.

Executive pay

4D Molecular Therapeutics's chief executive was paid a total of $2.1M for the year ended Dec 31, 2025, up 103% from $1M the year before. In the last 12 months, 4D Molecular Therapeutics's executives and directors bought no stock on the open market and sold $5.4M.

Chief executive, total pay$2.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.